Zoetis Inc. (ZTS) Earnings
Zoetis Inc. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $1.85. ZTS has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise +1.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $1.60 | $1.53 | -4.4% | $2.3B | -1.7% |
| Feb 12, 2026 | $1.40 | $1.48 | +5.7% | $2.4B | +1.1% |
| Feb 13, 2025 | $1.37 | $1.40 | +2.2% | $2.3B | +0.9% |
| May 2, 2024 | $1.34 | $1.38 | +3.0% | $2.2B | +1.7% |
| Feb 13, 2024 | $1.32 | $1.24 | -6.1% | $2.2B | +1.1% |
| Nov 2, 2023 | $1.36 | $1.36 | +0.0% | $2.2B | -1.4% |
| May 4, 2023 | $1.26 | $1.31 | +4.0% | $2.0B | -0.6% |
| Feb 14, 2023 | $1.05 | $1.15 | +9.5% | $2.0B | +1.8% |
| Nov 3, 2022 | $1.24 | $1.21 | -2.4% | $2.0B | -3.9% |
| Aug 4, 2022 | $1.22 | $1.20 | -1.6% | $2.1B | +1.3% |
| May 5, 2022 | $1.23 | $1.32 | +7.3% | $2.0B | +0.4% |
| Feb 15, 2022 | $0.96 | $1.00 | +4.2% | $2.0B | +1.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Kristen Peck mentioned headline numbers: organic operational revenue flat, adjusted net income grew 1%. International segment had 10% organic operational revenue growth, U.S. declined 8%. By species, livestock had 12% organic operational revenue growth, companion animal declined 4%. Outlined interconnected dynamics in companion animals: pricing in veterinary clinics rising slower, pet owners price sensitive, intensified competition, and no market expansion. Talked about OA pain, diagnostics strength in companion animals, livestock broad-based performance. Mentioned actions on multiple fronts: sharpening execution across core commercial levers, accelerating science-to-scale model, announcing acquisition of Neogen's animal genomics business, and sharpening capital allocation with cost and productivity program. Watney discussed quarterly performance reflecting converging dynamics, financial results, and segment results.
Guidance
For full year 2026, on organic operational basis, expect revenue growth of 2% to 5% and adjusted net income growth of 2% to 6%. Q1 2026 had zero organic under new math, but guiding to low single to mid single digit growth for full year, with easier comps in second half and calendar switch benefits.
Segment performance
On an organic operational basis, revenue was flat and adjusted net income grew 1%. International segment delivered 10% organic operational revenue growth, U.S. declined 8%. Livestock delivered 12% organic operational revenue growth, companion animal declined 4% operationally. Global revenue was $2.3 billion, flat on organic operational basis. U.S. revenue $1.1 billion, declined 8%. International segment revenue grew 17% on reported basis and 10% on organic operational basis. U.S. companion animal posted $865 million, declined 11%. International companion animal reported $654 million in sales, growing 7%. International livestock contributed $495 million, with growth of 14%.
Risks & headwinds
Factors like continued price sensitivity in pet owners, intensified competition across key pet care categories, lower clinic traffic, and potential impact of foreign currency, acquisitions, divestitures on growth.